Phase I trial design: Are new methodologies being put into practice?

Annals of Oncology

Volumn 7, Issue 6, 1996, Pages 561-566

  Dent, S F ^a   Eisenhauer, E A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Methodology; Phase I trials

Indexed keywords

15 DEOXYSPERGUALIN; 4 (3,3 DIMETHYL 1 TRIAZENO)BENZOIC ACID; ADOZELESIN; ANTINEOPLASTIC AGENT; BREQUINAR; BRYOSTATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; LOBAPLATIN; MENOGARIL; MITONAFIDE; PACLITAXEL; PEMETREXED; SR 95325; SULOFENUR; SURAMIN; SWAINSONINE; TALLIMUSTINE; TELOXANTRONE; TETRAPLATIN; TOPOTECAN; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0029841357     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010671     Document Type: Review

References (60)

1. Rozencweig M, Staquet M, Hansen HH et al. EORTC Guidelines for phase I trials with single agents in adults. Eur J Cancer Clin Oncol 1985; 21: 1005-9.
2. Kerr DJ. Phase I clinical trials: Adapting methodology to face new challenges. Ann Oncol 1994; 5: S67-S70.
3. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
4. O'Quigley J. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. Biometrics 1992; 48: 853-62.
5. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149-61.
6. Collins JM, Zaharko DS, Dedrick RL et al. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986; 70: 73-80.
7. Mick R, Ratain MJ. Model-guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision. J Natl Cancer Inst 1993; 85: 217-23.
8. Hawkins MJ. Early Cancer clinical trials: Safety, numbers and consent. J Natl Cancer Inst 1993; 85: 1618-19.
9. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I clinical trials based on preclinical development. J Natl Cancer Inst 1990; 82: 1321-6.
10. Smith TL, Lee JJ, Kantarjian HM et al. Design and results of phase I cancer clinical trials: Three-year experience at M.D. Anderson Cancer Center. J Clin Oncol 1996; 14: 287-95.
11. Mick R, Lane N, Daugherty C et al. Physician-determined patient risk of toxic effects: Impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst 1994; 86: 1685-93.
12. Graham MA, Kaye SB. New approaches in preclinial and clinical pharmacokinetics. Cancer Surv 1993; 17: 27-47.
13. Ratain MJ, Mick R, Schilsky RL et al. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993; 85: 1637-43.
14. Christian MC, Korn EL. The limited precision of phase I trials. J Natl Cancer Inst 1994; 86: 1662-3.
15. Tomiak E, Piccart MJ, Kerger J et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994; 12: 1458-67.
16. Verweij J, Lund B, Beijnen J et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993; 4: 673-8.
17. Haas NB, LaCreta FP, Walczak J et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54: 1220-6.
18. Sessa C, Pagani O, Zurlo MG et al. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 1994; 5: 901-7.
19. Goss PE, Baptiste J, Fernandes B et al. Phase I study of swainsonine in patients with advanced malignancies. Cancer Res 1994; 54: 1450-7.
20. Vogelzang NJ, Mick R, Janisch, L et al. Phase I and pharmacokinetic study of a new antineoplastic agent: Pyrazine diazohydroxide (NSC 361456). Cancer Res 1994; 54: 114-9.
21. Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-36.
22. Belanger K, Jolivet J, Maroun J et al. Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole. Invest New Drugs 1993; 11: 301-8.
23. Rothenberg ML, Kuhn JG, Burris HA III et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-204.
24. Schilder RJ, LeCreta FP, Perez RP et al. Phase I and pharmacokinetic study of ormaplatin (Tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 1994; 54: 709-17.
25. Kattan J, Durand M, Droz JP et al. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule. Am J Clin Oncol 1994; 17: 242-5.
26. de Forni M, Bugat R, Chabot GG et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-54.
27. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9.
28. Jayson GC, Crowther D, Prendiville J et al. Phase I trial of bryostatin I in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995; 72: 461-8.
29. Fleming GF, Ratain MJ, O'Brien SM et al. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst 1994; 86: 368-72.
30. Pollera CF, Ceribelli A, Crecco M et al. Weekly gemcitabine in advanced or metastatic solid tumors a clinical phase I study. Invest New Drugs 1994; 12: 111-9.
31. van Warmerdam LJC, ten Bokkel Huinink WW, Rodenhuis S et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 1995; 13: 1768-76.
32. Rinaldi DA, Burris HA, Dorr FA et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13: 2842-50.
33. Diaz-Rubio E, Martin M, Lopez-Vega JM et al. Phase I study of mitonafide with a 3-day administration schedule: Early interruption due to severe central nervous system toxicity. Invest New Drugs 1994; 12: 277-81.
34. Gietema JA, de Vries EGE, Sleijfer DT et al. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer 1993; 67: 396-401.
35. Foster BJ, Newell DR, Gumbrell et al. Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer 1993; 67: 369-73.
36. Foster BJ, Newell DR, Carmichael J et al. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer 1993; 67: 362-8.
37. Burris H, Irvin R, Kuhn J et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993; 11: 950-8.
38. Gietema JA, Guchelaar HJ, de Vries EGE et al. A phase I study of lobaplatin (D-19466) administered by 72 hours continuous infusion. Anti-Cancer Drugs 1993; 4: 51-5.
39. de Forni M, Chabot GG, Armand JP et al. Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients. Eur J Can 1993; 29A: 983-8.
40. Abigerges D, Chabot GG, Armand JP et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-21.
41. Schiller JH, Storer B, Tutsch K et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241-8.
42. Bissett D, Setanoians A, Cassidy J et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993; 53: 523-7.
43. Schellens JHM, Planting AST, van Acker BAC et al. Phase I and pharmacologic study of the novel indoloquinone bio-reductive alkylating cytotoxic drug E09. J Natl Cancer Inst 1994; 86: 906-12.
44. Ray MS, Muggia FM, Leichman CG et al. Phase I study of (6R)-5,10-dideazatetrahydrofolate; A folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 1993; 85: 1154-8.
45. Extra J-M, Rousseau F, Bruno R et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-42.
46. Prendiville J, Crowther D, Thatcher N et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993; 68: 418-24.
47. Saltz L, Sirott M, Young C et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumours, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499-1507.
48. Rowinsky ER, Noe DA, Grochow LB et al. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 1995; 13: 1975-84.
49. Weiss GR, Brown TD, Kuhn JG et al. A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril. Invest New Drugs 1993; 11: 17-27.
50. Dhodapkar MV, Richardson RL, Reid JM et al. Pyrazine diazohydroxide (NSC-361456). Invest New Drugs 1994; 12: 207-16.
51. Kobayashi K, Vokes EE, Vogelzang NJ et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995; 13: 2196-207.
52. Supko JG, Balcerzak P, Kraut EH. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Cancer Res 1993; 53: 4843-9.
53. Johnson BE, Parker R, Tsai CM et al. Phase I trial of dihydrolenperone in lung cancer patients: A novel compound with in vitro activity against lung cancer. Invest New Drugs 1993; 11: 29-37.
54. Havlin KA, Kuhn JG, Koeller J et al. Deoxyspergualin: Phase I clinical, immunologic and pharmacokinetic study. Anti-Cancer Drugs 1995; 6: 229-36.
55. Shamdas GJ, Alberts DS, Modiano M et al. Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anti-Cancer Drugs 1994; 5: 10-14.
56. O'Rourke TJ, Weiss GR, New P et al. Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anti-Cancer Drugs 1994; 5: 520-6.
57. Burris HA III, Awada A, Kuhn JG et al. Phase I and pharmacokinetic studies of topotecan administered as a 72- or 120 hours continuous infusion. Anti-Cancer Drugs 1994; 5: 394-402.
58. Brown TD, O'Rourke TJ, Kuhn JG et al. Phase I trial of sulofenur (LY 186641) given orally on a daily × 21 schedule. Anti-Cancer Drugs 1994; 5: 151-9.
59. Catimel G, Chabot GG, Guastalla JP et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133-40.
60. Swain SM, Perker B, Wellstein A et al. Phase I trial of pentosan polysulfate. Invest New Drugs 1995; 13: 55-62.